institute of aging - Hôpital des Charpennes
Villeurbanne, 69100, France
Location status: Recruiting
Location contact
Teddy NOVAIS, PharmD, PhD
CONTACT
NCT Number: NCT05741593
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
Interested in participating?
Request Info65 year–100 year
All sexes
Observational
Villeurbanne, 69100, France
Location status: Recruiting
Teddy NOVAIS, PharmD, PhD
CONTACT
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.
In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.
However, the effectiveness of these strategies is optimal if and only if patients adhere to them.
In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
recorded semi-structured interviews between the patients and the pharmacist
Time frame: one year
Describing the content of discussions, relating to antithrombotic treatment for secondary prevention, between elderly patients previously treated with antithrombotics and admitted to hospital for an ischemic stroke and a pharmacist
Time frame: 15 to 60 minutes per patient
Exploring patients' representations and beliefs regarding antithrombotics before and after the onset of stroke or recurrence of stroke
Time frame: 15 to 60 minutes per patient
Explore patients' medication adherence to antithrombotics before the onset of stroke or recurrence of stroke
Time frame: 15 to 60 minutes per patient
Explore the impact of stroke occurrence or stroke recurrence on patient medication adherence (including motivation, ambivalence, confidence in medication benefits)
Time frame: 15 to 60 minutes per patient
Identify the barriers and levers to drug adherence with antithrombotics
Contact information is provided by the study sponsor or research team.
Hospices Civils de Lyon
Other
Acronym: QUATRO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05963568
Behavior, Brain Diseases
Parakou, Benin
View Trial DetailsNCT05997914
Adherence, Medication, Anticoagulants and Bleeding Disorders
Jacksonville, Florida, United States
View Trial DetailsNCT03185858
Behavior, Brain Diseases
Xingtai, Hebei, China
View Trial DetailsNCT02089074
Behavior, Brain Diseases
Ålesund, Norway
View Trial Details